Epipharyndeal Abrasion Therapy (EAT) for glomerulopathy

Effect of epipharyndeal abrasion therapy (EAT) on the remission of glomerulopathy. - EAT on the remission of glomerulopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190011

Enrollment

Registered

2019-04-10

Start date

2012-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glomerulonephropathy glomerulonephropathy

Interventions

apply 0.5% Zinc chloride to epipharynx transnasal and orally once a <1 week (responsibility of nephrologists) take 0.5% Zinc chloride as nose drops once a day ( responsibility of patients themselves

Zinc chloride

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) glomerular disease (proved by renal biopsy) 2) need for epipharyngeal treatment 3) provided informed consent

Exclusion criteria

Exclusion criteria: 1) pregnancy 2) lactation 3) negative opinion judged by attending doctor

Design outcomes

Primary

Measure	Time frame
diminishment of proteinuria (<30mg/gCre) or hematuria (RBC 0/HPF)	—

Secondary

Measure	Time frame
time from when epipharyndeal abrasion therapy was started until when proteinuria or hematuria is diminished, as well as safety information	—

Contacts

Public ContactMichio Fukuda

Nagoya City University Hospital

m-fukuda@med.nagoya-cu.ac.jp+81-52-853-8221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026